Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/34134
Title: | Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions |
Authors: | ACKERMANN, Christoph Jakob; STOCK, Gustavo; TAY, Rebecca; DAWOD, Mohammed; GOMES, Fabio; CALIFANO, Raffaele |
Citation: | ONCOTARGETS AND THERAPY, v.12, p.7857-7864, 2019 |
Abstract: | Approximately 1-2% of unselected patients with Non-small Cell Lung Cancer (NSCLC) harbor RET rearrangements resulting in enhanced cell survival and proliferation. The initial treatment strategy for RET rearranged NSCLC has been multi-target tyrosine kinase inhibition. With overall response rates (ORR) of 16-53% and a median progression-free survival (PFS) of 4.5-7.3 months these outcomes are clearly inferior to the efficacy outcomes of selective tyrosine kinase inhibitors (TKI) in other oncogene-addicted NSCLC. Additionally, multi-kinase inhibition in RET-driven NSCLC patients showed concerning rates of high-grade toxicity, mainly induced by anti-VEGFR-kinase activity. Novel selective RET inhibitors like BLU-667, LOXO-292 and RXDX-105 have been recently investigated in early phase clinical trials showing promising efficacy with a manageable toxicity profile. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/ICESP Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_ACKERMANN_Targeted_Therapy_For_RETRearranged_NonSmall_Cell_Lung_Cancer_2019.PDF | publishedVersion (English) | 353.74 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.